Show simple item record

dc.contributor.advisorHolz, Marina K.en_US
dc.contributor.authorWiener, Sara Leora
dc.date.accessioned2019-07-10T19:27:14Z
dc.date.available2019-07-10T19:27:14Z
dc.date.issued2018-04-25
dc.identifier.citationWiener, Sara Leora. Combination of Rapamycin and Resveratrol for Treatment of Bladder Cancer Presented to the S. Daniel Abraham Honors Program in Partial Fulfillment of the Requirements for Completion of the Program Stern College for Women Yeshiva University April 25, 2018.en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12202/4518
dc.identifier.urihttps://ezproxy.yu.edu/login?url=http://repository.yu.edu/handle/20.500.12202/4518
dc.descriptionThe file is restricted for YU community access only.en_US
dc.description.abstractLoss of TSC1 function, a crucial negative regulator of mTOR signaling, is a common alteration in bladder cancer. Mutations in other members of the PI3K pathway, leading to mTOR activation, are also found in bladder cancer. This provides rationale for targeting mTOR for treatment of bladder cancer characterized by TSC1 mutations and/or mTOR activation. In this study, we asked whether combination treatment with rapamycin and resveratrol could be effective in concurrently inhibiting mTOR and PI3K signaling and inducing cell death in bladder cancer cells. In combination with rapamycin, resveratrol was able to block rapamycin-induced Akt activation, while maintaining mTOR pathway inhibition. In addition, combination treatment with rapamycin and resveratrol induced cell death specifically in TSC1-/- MEF cells, and not in wild-type MEFs. Similarly, resveratrol alone or in combination with rapamycin induced cell death in human bladder cancer cell lines. These data indicate that administration of resveratrol together with rapamycin may be a promising therapeutic option for treatment of bladder cancer.en_US
dc.description.sponsorshipS. Daniel Abraham Honors Program of Stern College for Women and the Holz Lab.en_US
dc.language.isoen_USen_US
dc.publisherStern College for Women Yeshiva University.en_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.subjectsenior honors thesisen_US
dc.subjectBladder Canceren_US
dc.subjectRapamycinen_US
dc.subjectResveratrolen_US
dc.subjectcancer treatmenten_US
dc.titleCombination of Rapamycin and Resveratrol for Treatment of Bladder Cancer.en_US
dc.typeThesisen_US


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 United States
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 United States